Literature DB >> 15863646

Severity of obstructive airway disease and risk of osteoporotic fracture.

F de Vries1, T P van Staa, M S G M Bracke, C Cooper, H G M Leufkens, J-W J Lammers.   

Abstract

The use of inhaled corticosteroids has been associated with a dose-related increased risk of fracture. This may be related to systemic absorption. However, several studies have found that patients with more severe reductions in pulmonary function had reduced bone mineral density, independent of inhaled corticosteroids. The objective of this study was to evaluate the relationship between disease severity and fracture risk. A large case-control study (108,754 cases) was conducted using data from the UK General Practice Research Database. It was found that higher doses of inhaled corticosteroids were associated with greater risks of fracture. The crude odds ratio of fracture among patients exposed to >1,600 microg beclomethasone equivalents per day was 1.95 (95% confidence interval (CI) 1.68-2.27). When adjustments were made for disease severity and use of bronchodilators, the initial dose-response relationship between inhaled corticosteroids and fracture risk disappeared (adjusted odds ratio of 1.19 (95% CI 1.01-1.41)). In conclusion, patients with severe obstructive airway disease are at risk of fracture. However, adequate adjustment for disease severity is essential when the association between the use of inhaled corticosteroids and risk of osteoporotic fracture is studied in observational research.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15863646     DOI: 10.1183/09031936.05.00058204

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  46 in total

Review 1.  [Comorbidities of COPD].

Authors:  H Watz; H Magnussen
Journal:  Internist (Berl)       Date:  2006-09       Impact factor: 0.743

Review 2.  Inhaled corticosteroids and the risk of fractures in older adults: a systematic review and meta-analysis.

Authors:  Mahyar Etminan; Mohsen Sadatsafavi; Saeedreza Ganjizadeh Zavareh; Bahi Takkouche; J Mark FitzGerald
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

3.  Pioglitazone and bladder cancer: two studies, same database, two answers.

Authors:  Frank de Vries; Maurice Zeegers; Maria E Goossens
Journal:  Br J Clin Pharmacol       Date:  2013-09       Impact factor: 4.335

4.  Factors associated with low bone mineral density in patients with cystic fibrosis.

Authors:  Shahid Sheikh; Susan Gemma; Alpa Patel
Journal:  J Bone Miner Metab       Date:  2014-03-16       Impact factor: 2.626

5.  Plasma inflammatory mediators associated with bone metabolism in COPD.

Authors:  Jessica M Bon; Yingze Zhang; Steven R Duncan; Joseph M Pilewski; Diana Zaldonis; Adriana Zeevi; Kenneth R McCurry; Susan L Greenspan; Frank C Sciurba
Journal:  COPD       Date:  2010-06       Impact factor: 2.409

6.  Is lung function associated with bone mineral density? Results from the Hertfordshire Cohort Study.

Authors:  E M Dennison; D K Dhanwal; S O Shaheen; R Azagra; I Reading; K A Jameson; A A Sayer; C Cooper
Journal:  Arch Osteoporos       Date:  2013-01-15       Impact factor: 2.617

7.  The Association Between Bone Mineral Density and Airflow Limitation in a Cohort of Fit Elderly Women.

Authors:  Caterina Trevisan; A Vianello; N Veronese; S Carraro; S Pizzato; P Lucato; G Girotti; C Rinaldo; A Coin; E Manzato; G Sergi
Journal:  Lung       Date:  2016-10-03       Impact factor: 2.584

Review 8.  Salmeterol/fluticasone propionate: a review of its use in the treatment of chronic obstructive pulmonary disease.

Authors:  Gillian M Keating; Paul L McCormack
Journal:  Drugs       Date:  2007       Impact factor: 9.546

9.  Use of beta2 agonists and risk of acute myocardial infarction in patients with hypertension.

Authors:  Frank de Vries; Sander Pouwels; Madelon Bracke; Jan-Willem Lammers; Olaf Klungel; Hubert Leufkens; Tjeerd van Staa
Journal:  Br J Clin Pharmacol       Date:  2008-02-12       Impact factor: 4.335

Review 10.  Long-term therapy in COPD: any evidence of adverse effect on bone?

Authors:  Arnulf Langhammer; Siri Forsmo; Unni Syversen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.